A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia

1. Panayiotidis, P.
2. Tumyan, G.
3. Thieblemont, C.
4. Ptushkin, V.V.
5. Marin-Niebla, A.
6. García-Sanz, R.
7. Le Gouill, S.
8. Stathis, A.
9. Bottos, A.
10. Hamidi, H.
11. Katz, P.
12. Perretti, T.
13. Willis, J.C.
14. Buske, C.